AI-Driven Biotech Firm Envisagenics Secures Series A Financing
New York-based AI-driven biotech company Envisagenics has secured Series A financing. The company focuses on discovering and developing novel RNA splicing therapeutics, using its advanced AI/ML platform.
The funding round was led by Red Cell Partners, with investments also coming from Microsoft's M12, Madrona Venture Group, Third Kind Venture Capital, Dynamk Capital, and New York Ventures. The company will use the funds to scale its drug discovery platform and biopharmaceutical partnerships. Envisagenics' SpliceCore® discovery platform is significantly more effective than traditional gene-centric discovery tools, increasing the likelihood of discovering novel targets by up to 250 times. The company is minority- and woman-led, promoting diversity in the biotech industry.
Envisagenics' Series A financing, led by Red Cell Partners, will support the growth of its innovative drug discovery platform and biopharmaceutical partnerships. The company's cutting-edge technology and diverse leadership are expected to drive advancements in RNA splicing therapeutics.
Read also:
- New Immigration Law Guide: Practical Advice for Legal Professionals
- Willich's Senior Citizens Prepare for Council Elections, City Celebrates International Day of Older Persons
- Chronic Stress: Holistic Management for Physical and Mental Health
- St. John's Hospital in Pay Dispute Over CEO's Salary Increase
